Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoGen initiates clinical bone marrow cancer trials
The primary objective of the phase I study is to evaluate the safety of huN901-DM1 in patients with relapsed or refractory multiple myeloma, and to identify the maximum
The primary objective of the phase I study is to evaluate the safety of huN901-DM1 in patients with relapsed or refractory multiple myeloma, and to identify the maximum
The alliance will combine the research expertise and understanding of disease mechanism and pathway biology of Novartis with Alnylam’s leading position in the field of RNA interference (RNAi).
MN-001, which is orally administered, is a leukotriene receptor antagonist and an inhibitor of phosphodiesterases III and IV, 5-lipoxygenase, and thromboxane A2. MediciNova licensed it from Kyorin Pharmaceutical
The recommendation of the advisory committee makes it likely that the drug will be given final approval by the FDA, although the agency is not bound by the
Proquad is the first and only vaccine approved in the US to help protect against these four diseases in a single shot. Proquad is also approved for use
In the study, M-Vax, an AC vaccine therapeutic, will be given as a first-line treatment to non-small cell lung cancer (NSCLC) patients after surgery. The study endpoints include
The regulator has designated Andrx with Official Action Indicated status, and has issued the company with a list of inspectional observations. Andrx has submitted a detailed response to
The preclinical report, conducted by research affiliates of the National Institutes of Health at Utah State University, compared the relative protection conveyed by Roche’s Tamiflu flu vaccine and
Of the participants in the study, 83% of those with moderate to severe migraine were either pain-free or had only mild pain two hours after treatment with GelStat
The trial of 7,599 symptomatic heart failure patients who had no previous diagnosis of diabetes provides statistically significant evidence that Atacand can reduce the risk of diabetes in